Viromed Medical AGFRA:VME +0.74%22 Return-on-Tangible-Equity is 12.48% as of Dec. 2025. GuruFocus rates FRA:VME with a GF Score™ of 22/100. The stock has 5 warning signs investors should review. Among 758 Medical Devices & Instruments companies, Viromed Medical AG ranks better than 52.24% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Viromed Medical AG's annualized net income for the quarter that ended in Dec. 2025 was €1.77 Mil. Viromed Medical AG's average shareholder tangible equity for the quarter that ended in Dec. 2025 was €14.18 Mil. Therefore, Viromed Medical AG's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 12.48%.
The historical rank and industry rank for Viromed Medical AG's Return-on-Tangible-Equity or its related term are showing as below:
FRA:VME'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -21.79 Med: -1.58 Max: 7.42
Current: 4.94
During the past 5 years, Viromed Medical AG's highest Return-on-Tangible-Equity was 7.42%. The lowest was -21.79%. And the median was -1.58%.
FRA:VME's Return-on-Tangible-Equity is ranked better than 52.24% of 758
companies
in the Medical Devices & Instruments industry
Industry Median: 4.08
vs FRA:VME: 4.94
Viromed Medical AG (FRA:VME) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Viromed Medical AG Return-on-Tangible-Equity Related Terms
Viromed Medical AG Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Viromed Medical AG's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viromed Medical AG Return-on-Tangible-Equity Chart
FRA:VME vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Viromed Medical AG's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viromed Medical AG Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Viromed Medical AG's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Viromed Medical AG's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 12.48% mean?
Viromed Medical AG (FRA:VME) has a Return-on-Tangible-Equity of 12.48% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Viromed Medical AG and its competitors. According to the industry distribution chart, Viromed Medical AG ranks #362 out of 758 companies in the Medical Devices & Instruments industry, placing it in the top 47.8%.
Is Viromed Medical AG's Return-on-Tangible-Equity too high?
Viromed Medical AG's current Return-on-Tangible-Equity is 12.48%. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.08. Viromed Medical AG's value of 12.48% is 205.9% above this industry median. Based on the distribution chart, Viromed Medical AG ranks #362 out of 758 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Viromed Medical AG has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Viromed Medical AG's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Viromed Medical AG ranks #362 out of 758 companies for Return-on-Tangible-Equity. This puts Viromed Medical AG in the upper half of its industry. The industry median Return-on-Tangible-Equity is 4.08. Viromed Medical AG's value of 12.48% is 205.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.08, based on 758 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Viromed Medical AG's current Return-on-Tangible-Equity of 12.48% is 205.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Viromed Medical AG and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viromed Medical AG's current Return-on-Tangible-Equity is 12.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viromed Medical AG stock overvalued right now?
Viromed Medical AG (FRA:VME) has a current Return-on-Tangible-Equity of 12.48%. The current Return-on-Tangible-Equity is 12.48% and 205.9% above the Medical Devices & Instruments industry median of 4.08. Viromed Medical AG's overall GF Score™ is 22/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Viromed Medical AG (FRA:VME), the current Return-on-Tangible-Equity is 12.48% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Viromed Medical AG is a medical technology company. It focuses on using cold plasma technology to develop medical solutions that protect people from viruses, bacteria, and multi-resistant germs. Viromed's product offerings include ViroCAP, a medical device based on cold plasma technology for treating wounds; ViroCAP derma-podo, a medical device that uses cold atmospheric plasma therapy for skin and foot care; and a Raumluftentkeimer. The company covers the entire value chain from research and development to production, logistics, marketing, and sales of its products.
22GF Score
Get the complete analysis for FRA:VME
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VME has been successfully added to your 
